🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢 CRIS contra el cáncer and Gustave Roussy are partnering to offer an exciting opportunity for a talented early career clinician scientist to develop their academic skills and expertise. 🗓️ Deadline open until 28 February ⬇ ⬇ ⬇ criscancer.org/es/gustaverous…

📰 This study published in Radiology, led by researchers from Gustave Roussy, aimed to evaluate tumor fraction (TF) in liquid biopsy as a potential surrogate for total tumor volume (TTV) measured on CT across 1,065 patients with metastatic cancer. 🔗doi.org/10.1148/radiol…

📰 We are thrilled to share our paper in Nature Reviews Cancer: "The Evolutionary Theory of Cancer: Challenges and Potential Solutions" by Lucie Laplane (Gustave Roussy) and Carlo Maley (Arizona State University). Read the full paper here ⤵ nature.com/articles/s4156…

🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀 📅 June 17-18, 2025 📍 Paris, France 🌍 Bringing together top researchers, clinicians, and industry leaders 🔗 Register now and be part of the conversation: aiinoncology.com

📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de Gustave Roussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique. 🔗 gustaveroussy.fr/fr/news-5-ques…

🚀 Congrès IFODS 2025 🚀 📄 Retrouvez tous les détails dans le programme ci-dessous et via la page : ifods.com. IFODS 2025, le rendez-vous de l’oncologie française ! 🎯

📰 Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine. 🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans. More informations 👉 gustaveroussy.fr/en/news-gustav…

📰 “De-escalation in Lung Cancer Treatment: Are We Ready?” A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy. 🔗 ascopubs.org/doi/full/10.12…

📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses. L’équipe Inserm dirigée par Thomas Mercher à Gustave Roussy a réussi à modéliser pour la première fois le développement d’une leucémie aiguë myéloïde en partant de

📰 Low-dose gut radiation enhances immunotherapy. New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment. #Immunotherapy #Oncology #PDL1

📣 We are excited to announce the first scientific day on liquid biopsy, organized by Gustave Roussy and the Prism Center, taking place on June 11, 2025, in Paris! 🧬🔬 🔗 More information & registration: gustaveroussy.my.site.com/formation/s/fo…

📢 New publication from Gustave Roussy researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢 Read the study: doi.org/10.1038/s43018…

New data in pancreatic #cancer! The NEOPAN Phase III trial led by Prof. Michel Ducreux (Gustave Roussy) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL. 👉 doi.org/10.1200/JCO-24… #PancreaticCancer #OncoResearch #FOLFIRINOX

📰 Beyond RET Inhibitors: New Targets Emerging in RET+ Lung #Cancer Mihaela Aldea / Arianna Marinello, MD / RETpositive Read publication: jamanetwork.com/journals/jamao…